Jennifer M Buszka, WHNP-BC
Community Health · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jennifer M Buszka’s office at (888) 731-8994 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$20,613
Medicare paid this office $20,613 for 192 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 86 | $6,682 | $62 |
| Return visit (30+ min) | 53 | $5,198 | $91 |
| New patient visit (45+ min) | 39 | $3,429 | $88 |
| Telephone medical discussion with physician, 11-20 minutes | 31 | $1,538 | $48 |
| Short return visit | 20 | $910 | $40 |
See all 6 services
| Short return visit (20+ min) | 86 | $6,682 | $62 |
| Return visit (30+ min) | 53 | $5,198 | $91 |
| New patient visit (45+ min) | 39 | $3,429 | $88 |
| Telephone medical discussion with physician, 11-20 minutes | 31 | $1,538 | $48 |
| Short return visit | 20 | $910 | $40 |
| Ultrasound measurement of bladder capacity after voiding | 56 | $445 | $8 |
Procedures year by year
| Procedure | 2013 | 2014 | 2023 | 2024 |
|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | – | – | 266 | 57 |
| Simple change of bladder tube | – | 34 | – | – |
| Fitting and insertion of vaginal support device | – | – | 21 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
192 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 16% · Women 100% · Also on Medicaid 17% · Health risk score 1.08. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 57% · Depression 30% · Diabetes 22% · Coronary heart disease 17% · Chronic kidney disease 16% · Heart failure 15% · Cancer 13% · COPD 13% · Atrial fibrillation 11% · Dementia 10% · Stroke 9%.
The office billed $98,803, Medicare allowed $29,702 and paid $20,613; for 356 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 192 | 356 | 76 | 1.08 | $98,803 | $20,613 |
| 2023 | 278 | 798 | 75 | 1.07 | $167,545 | $36,126 |
| 2014 | 25 | 44 | 71 | 2.89 | $9,506 | $2,550 |
| 2013 | 1,159 | 3,697 | 76 | 3.53 | $386,020 | $238,801 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| New patient visit (30+ min) | 123 | $9,506 | $77 |
| Telephone medical discussion with physician, 11-20 minutes | 82 | $6,433 | $66 |
| Short return visit (20+ min) | 75 | $5,767 | $64 |
| Telephone medical discussion with physician, 5-10 minutes | 60 | $2,849 | $41 |
| Ultrasound measurement of bladder capacity after voiding | 234 | $2,566 | $10 |
| New patient visit (45+ min) | 19 | $2,275 | $120 |
| Short return visit | 46 | $2,179 | $39 |
| Fitting and insertion of vaginal support device | 15 | $1,150 | $55 |
| Pessary, reusable, non rubber, any type | 15 | $1,088 | $52 |
| New patient visit (15+ min) | 13 | $600 | $46 |
2014: 1 service
| Simple change of bladder tube | 19 | $2,130 | $63 |
2013: 10 services
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 610 | $95,888 | $62 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 464 | $38,733 | $47 |
| Subsequent nursing facility care with high level of medical decision making, per day at least 45 minutes | 196 | $35,220 | $92 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 250 | $30,344 | $116 |
| Initial nursing facility care with moderate level of medical decision making, per day at least 35 minutes | 167 | $15,494 | $91 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 205 | $8,692 | $30 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 20 | $4,212 | $62 |
| Initial nursing facility care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $3,179 | $65 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 13 | $1,625 | $116 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 15 | $1,374 | $47 |
Drugs they prescribed that Part D paid
$63,899
Pharmacies billed $63,899 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 405) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
341 generic and 64 brand-name prescriptions · $63,899 in drug cost · 110 antibiotic prescriptions to 64 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 31 | $23,710 | $765 |
| Myrbetriq | 26 | $14,852 | $571 |
| Estradiol | 135 | $10,898 | $81 |
| Solifenacin | 41 | $7,657 | $187 |
| Tolterodine Tartrate Er | 14 | $2,787 | $199 |
See all 10 drugs
| Gemtesa | 31 | $23,710 | $765 |
| Myrbetriq | 26 | $14,852 | $571 |
| Estradiol | 135 | $10,898 | $81 |
| Solifenacin | 41 | $7,657 | $187 |
| Tolterodine Tartrate Er | 14 | $2,787 | $199 |
| Methenamine Hippurate | 14 | $862 | $62 |
| Nitrofurantoin | 18 | $780 | $43 |
| Cephalexin | 61 | $616 | $10 |
| Nitrofurantoin Mono-Macro | 15 | $267 | $18 |
| Tamsulosin | 11 | $67 | $6 |
Year by year
| 2024 | 405 | 202 | 0% (0) | 16% | $63,899 |
| 2023 | 517 | 262 | 0% (0) | 12% | $71,929 |
| 2022 | 42 | 22 | 0% (0) | 48% | $116,022 |
| 2021 | 407 | 275 | 0% (0) | 21% | $135,528 |
| 2020 | 477 | 319 | None | 16% | $79,420 |
| 2019 | 691 | 434 | None | 22% | $55,107 |
| 2018 | 700 | 426 | None | None | $117,189 |
| 2017 | 526 | 327 | None | 19% | $36,773 |
| 2016 | 336 | 186 | 0% (0) | 18% | $20,179 |
| 2015 | 194 | 78 | 0% (0) | None | $9,829 |
| 2014 | 37 | 23 | 0% (0) | None | $2,522 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Myrbetriq | 24 | $19,998 | $833 |
| Gemtesa | 19 | $16,093 | $847 |
| Estradiol | 136 | $11,712 | $86 |
| Solifenacin | 71 | $11,184 | $158 |
| Tolterodine Tartrate Er | 31 | $4,524 | $146 |
| Cephalexin | 124 | $951 | $8 |
| Nitrofurantoin Mono-Macro | 34 | $558 | $16 |
| Nitrofurantoin | 15 | $319 | $21 |
2021: 7 drugs
| Myrbetriq | 21 | $16,819 | $801 |
| Tolterodine Tartrate Er | 27 | $5,018 | $186 |
| Tamsulosin | 41 | $1,209 | $29 |
| Nitrofurantoin Mono-Macro | 67 | $1,035 | $15 |
| Cephalexin | 106 | $440 | $4 |
| Finasteride | 15 | $309 | $21 |
| Ciprofloxacin | 34 | $133 | $4 |
2020: 8 drugs
| Myrbetriq | 25 | $19,994 | $800 |
| Tolterodine Tartrate Er | 26 | $3,849 | $148 |
| Tamsulosin | 64 | $1,324 | $21 |
| Nitrofurantoin Mono-Macro | 64 | $1,004 | $16 |
| Cephalexin | 145 | $574 | $4 |
| Oxybutynin Chloride | 13 | $356 | $27 |
| Ciprofloxacin | 27 | $120 | $4 |
| Sulfamethoxazole-Trimethoprim | 19 | $44 | $2 |
2019: 10 drugs
| Myrbetriq | 31 | $29,934 | $966 |
| Tolterodine Tartrate Er | 45 | $8,186 | $182 |
| Nitrofurantoin Mono-Macro | 128 | $1,981 | $15 |
| Oxybutynin Chloride Er | 33 | $1,456 | $44 |
| Tamsulosin | 69 | $1,448 | $21 |
| Cephalexin | 200 | $951 | $5 |
| Testosterone Cypionate | 15 | $642 | $43 |
| Nitrofurantoin | 13 | $613 | $47 |
| Ciprofloxacin | 22 | $100 | $5 |
| Sulfamethoxazole-Trimethoprim | 32 | $80 | $2 |
2018: 10 drugs
| Myrbetriq | 22 | $19,593 | $891 |
| Tolterodine Tartrate Er | 38 | $8,902 | $234 |
| Toviaz | 12 | $4,307 | $359 |
| Nitrofurantoin Mono-Macro | 133 | $2,094 | $16 |
| Tamsulosin | 92 | $1,340 | $15 |
| Oxybutynin Chloride Er | 20 | $821 | $41 |
| Cephalexin | 210 | $733 | $3 |
| Nitrofurantoin | 11 | $417 | $38 |
| Ciprofloxacin | 33 | $146 | $4 |
| Sulfamethoxazole-Trimethoprim | 50 | $124 | $2 |
2017: 9 drugs
| Vesicare | 21 | $15,052 | $717 |
| Myrbetriq | 16 | $12,332 | $771 |
| Tolterodine Tartrate Er | 12 | $2,864 | $239 |
| Nitrofurantoin Mono-Macro | 116 | $1,969 | $17 |
| Cephalexin | 187 | $755 | $4 |
| Tamsulosin | 50 | $737 | $15 |
| Ciprofloxacin | 25 | $96 | $4 |
| Sulfamethoxazole-Trimethoprim | 33 | $92 | $3 |
| Fluconazole | 12 | $45 | $4 |
2016: 8 drugs
| Myrbetriq | 15 | $7,122 | $475 |
| Tolterodine Tartrate Er | 24 | $4,741 | $198 |
| Tamsulosin | 87 | $2,065 | $24 |
| Nitrofurantoin Mono-Macro | 36 | $684 | $19 |
| Finasteride | 22 | $254 | $12 |
| Cephalexin | 45 | $159 | $4 |
| Ciprofloxacin | 19 | $71 | $4 |
| Sulfamethoxazole-Trimethoprim | 23 | $69 | $3 |
2015: 4 drugs
| Tolterodine Tartrate Er | 16 | $2,890 | $181 |
| Tamsulosin | 80 | $2,450 | $31 |
| Finasteride | 27 | $557 | $21 |
| Ciprofloxacin | 12 | $67 | $6 |
2014: 1 drug
| Tamsulosin | 11 | $320 | $29 |
Money from drug and device companies
$205 in 2025
| 2025 | 2 | 4 | None | $205 |
| 2024 | 2 | 5 | None | $207 |
| 2023 | 1 | 10 | None | $1,353 |
| 2022 | 7 | 11 | None | $267 |
| 2021 | 3 | 3 | None | $51 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Axonics | $133 | 1 payment
|
| Sumitomo Pharma America | Gemtesa | $72 | 3 payments
|
See all 4 published payments
| Sumitomo Pharma America | Meals · 2025-07-08 | Gemtesa | $27 |
| Boston Scientific | Meals · 2025-06-23 | Axonics | $133 |
| Sumitomo Pharma America | Meals · 2025-02-19 | Gemtesa | $21 |
| Sumitomo Pharma America | Meals · 2025-01-09 | Gemtesa | $23 |
See earlier years (2024, 2023, 2022, 2021)
2024: $207
| Axonics | Axonics | $148 | 2 payments
|
| Abbvie | Botox | $59 | 3 payments
|
2023: $1,353
| Axonics | Axonics | $1,353 | 10 payments
|
2022: $267
| Janssen Biotech | Stelara | $91 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $47 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $41 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $29 | 1 payment
|
| Genzyme | Dupixent | $23 | 1 payment
|
| Abbvie | Rinvoq | $19 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $17 | 1 payment
|
2021: $51
| Myriad Genetic Laboratories | Prolaris | $18 | 1 payment
|
| Teleflex | Urolift System | $17 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 73.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1487912812
- Licence
- MI 4704217875
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LC1500X (363LC1500X)
- Mailing address
- 195 Page Mill Rd Ste 103, Palo Alto, CA, 94306
- NPI first listed
- 2012-04-23
- NPI last updated
- 2025-12-08
- NPI record certified
- 2025-12-08
This is when the NPI record was last certified, not a medical board exam.